Kidney Week

Abstract: INFO07-TH

Cure Glomerulonephropathy Network (CureGN)

Session Information

• Informational Posters - 1
  November 06, 2025 | Location: Exhibit Hall, Convention Center
  Abstract Time: 10:00 AM - 12:00 PM

Category: Glomerular Diseases

• No subcategory defined

Authors

• Helmuth, Margaret, University of Michigan Michigan Medicine, Ann Arbor, Michigan, United States

Margaret Helmuth, MA

• Smith, Abigail R., Northwestern University, Chicago, Illinois, United States

Abigail R. Smith, PhD

• Bomback, Andrew S., Columbia University, New York, New York, United States

Andrew S. Bomback, MD, MPH

• Derebail, Vimal K., The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States

Vimal K. Derebail, MD, MPH, FASN

• Khalid, Myda, Riley Hospital for Children at Indiana University Health, Indianapolis, Indiana, United States

Myda Khalid, MD

• Sethna, Christine B., Northwell Health, New Hyde Park, New York, United States

Christine B. Sethna, MD, MEd

• Gadegbeku, Crystal A., Cleveland Clinic, Cleveland, Ohio, United States

Crystal A. Gadegbeku, MD, FASN

• Mariani, Laura H., University of Michigan Michigan Medicine, Ann Arbor, Michigan, United States

Laura H. Mariani, MD, MS, FASN

Group or Team Name

• The CureGN Consortium.

Description

CureGN is a multi-center, prospective observational cohort study of glomerular disease funded by the NIH-NIDDK. CureGN has enrolled 2,951 participants with minimal change disease, focal segmental glomerulosclerosis, membranous nephropathy, or IgA vasculitis with nephritis or nephropathy from 71 sites internationally since Dec. 2014.

Pediatric and adult patients biopsied within 5 years are eligible to participate. Exclusion criteria include kidney failure at enrollment, diabetes at biopsy, and glomerular disease attributed to a secondary cause. Sociodemographic, clinical, pathologic, and patient reported data collection is enriched by a diverse biorepository and digital pathology repository (DPR). Renal and non-renal outcomes are collected. Participant characteristics with median 5.8 year follow up are shown.

CureGN supports multi-dimensional translational research by combining clinical phenotype, pathology, and outcome data with longitudinally collected DNA, RNA, blood, and urine specimens. To date, whole genome sequencing and RNA sequencing has been performed on 2,000 and 2,124 patients, respectively. The DPR can provide annotated images or quantitative scoring data from kidney biopsies for investigators, and currently stores images from 1,835 patient biopsies, of which 1,202 are scored. An online data-sharing tool (tranSMART) is available to researchers for hypothesis generation.

The study objectives support a variety of ways to identify mechanistically distinct subgroups, discover/validate biomarkers, delineate disease-specific treatment targets, and inform future therapeutic trials to advance the diagnosis, care, and outcomes of glomerular diseases. Patient input into the study is integrated via a patient advisory panel. The Career Development Group provides peer mentoring for young investigators interested in glomerular disease. The consortium is open to ancillary study proposals from Network and extramural investigators.

Funding

• Funding for the CureGN consortium is provided by U24DK100845, U01DK100846, U01DK100876, U01DK100866, and U01DK100867 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Patient recruitment is supported by NephCure.